← Back to Clinical Trials
Recruiting NCT06760806

NCT06760806 Evaluation of Toxicities in Patients Treated With Palliative Radiotherapy at Policlinico Sant Orsola of Bologna.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06760806
Status Recruiting
Phase
Sponsor IRCCS Azienda Ospedaliero-Universitaria di Bologna
Condition Palliative Care
Study Type OBSERVATIONAL
Enrollment 7,000 participants
Start Date 2021-01-21
Primary Completion 2027-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 7,000 participants in total. It began in 2021-01-21 with a primary completion date of 2027-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The aim of the study is to assess the outcome in palliative patients, particularly in terms of symptom resolution or alleviation, after radiation treatment of the various tumours analysed, in relation to the treatment setting, dosages and techniques used both for newly diagnosed tumours and for cases already diagnosed and treated at the Radiotherapy Unit of the Sant Orsola Hospital.

Eligibility Criteria

Inclusion Criteria: * adult patients of either sex with a new or previous diagnosis of malignant neoplasm since 1st January 2000 * patients treated with paliative radiotherapy * obtaining of informed consent Exclusion Criteria: * adult patients of either sex with a new or previous diagnosis of malignant neoplasm who choose not to undergo radiotherapy treatment * patients enrolled in other studies * pregnant or breastfeeding women

Contact & Investigator

Central Contact

Alessio Giuseppe Morganti, MD

✉ alessio.morganti2@unibo.it

📞 0512143564

Principal Investigator

Alessio Giuseppe Morganti, MD

PRINCIPAL INVESTIGATOR

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Frequently Asked Questions

Who can join the NCT06760806 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Palliative Care. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06760806 currently recruiting?

Yes, NCT06760806 is actively recruiting participants. Contact the research team at alessio.morganti2@unibo.it for enrollment information.

Where is the NCT06760806 trial being conducted?

This trial is being conducted at Bologna, Italy.

Who is sponsoring the NCT06760806 clinical trial?

NCT06760806 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Alessio Giuseppe Morganti, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 7,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology